18,19-dinor-vitamin D compounds
First Claim
1. A compound having the formula:
- ##STR9## where X1 and X2, which may be the same or different, are each selected from hydrogen and a hydroxy protecting group, and where the group R is represented by the structure;
##STR10## where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, --OY, --CH2 OY, --C≡
CY and --CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, --CR5 O and a radical of the structure;
##STR11## where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5 -alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, =CR2 R3, or the group --(CH2)p --, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group --(CH2)q --, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl.
0 Assignments
0 Petitions
Accused Products
Abstract
18,19-dinor-vitamin D3 analogs in which the angular methyl group attached to carbon 13 of the CD-ring and the exocyclic methylene group attached to carbon 10 of the A-ring have been removed and replaced by a hydrogen atom. The 18,19-dinor vitamin D compounds are characterized by relatively high cell differentiation activity, and marked intestinal calcium transport activity while exhibiting lower activity than 1α,25-dihydroxyvitamin D3 in their ability to mobilize calcium from bone. These compounds would be useful for the treatment of diseases where bone formation is desired, such as osteoporosis, because of their preferential calcemic activity, and for the treatment of psoriasis due to their cell differentiation activity.
-
Citations
5 Claims
-
1. A compound having the formula:
- ##STR9## where X1 and X2, which may be the same or different, are each selected from hydrogen and a hydroxy protecting group, and where the group R is represented by the structure;
##STR10## where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, --OY, --CH2 OY, --C≡
CY and --CH=CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, --CR5 O and a radical of the structure;
##STR11## where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5 -alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, =CR2 R3, or the group --(CH2)p --, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group --(CH2)q --, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl. - View Dependent Claims (2, 3)
- ##STR9## where X1 and X2, which may be the same or different, are each selected from hydrogen and a hydroxy protecting group, and where the group R is represented by the structure;
-
4. 18,19-dinor-1α
- ,25-dihydroxyvitamin D3.
-
5. 18,19-dinor-1α
- -hydroxyvitamin D3.
Specification